Joshua A. Harrill, Bethany B Parks, Eliane Wauthier, J. Craig Rowlands, Lola M. Reid, Russell S. Thomas – 6 October 2014 – Rodent cancer bioassays indicate that the aryl hydrocarbon receptor (AHR) agonist, 2,3,7,8‐tetracholorodibenzo‐p‐dioxin (TCDD), causes increases in both hepatocytic and cholangiocytic tumors. Effects of AHR activation have been evaluated on rodent hepatic stem cells (rHpSCs) versus their descendants, hepatoblasts (rHBs), two lineage stages of multipotent, hepatic precursors with overlapping but also distinct phenotypic traits.

Filipe Nery, Sylvie Chevret, Bertrand Condat, Emmanuelle de Raucourt, Larbi Boudaoud, Pierre‐Emmanuel Rautou, Aurelie Plessier, Dominique Roulot, Cendrine Chaffaut, Valerie Bourcier, Jean‐Claude Trinchet, Dominique‐Charles Valla, on behalf of Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire – 6 October 2014 – In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence of the progression of liver disease.

Ioanna Parisi, James O'Beirne, Emmanuel Tsochatzis – 6 October 2014

Ira Hofer, John Spivack, Miguel Yaport, Jeron Zerillo, David L. Reich, David Wax, Samuel DeMaria – 4 October 2014 – The anesthesiologist has been recognized as an integral member of the liver transplant team, and previous studies have demonstrated that inter‐anesthesiologist variability can be a driver of outcomes for high‐risk patients. We hypothesized that anesthesiologist experience, defined as the number of previous liver transplants performed at our institution, the Icahn School of Medicine at Mount Sinai, would be independently associated with outcomes for liver transplant patients.

1 October 2014

1 October 2014

1 October 2014

1 October 2014

1 October 2014

1 October 2014